GE HealthCare Increases Access to Precision Care Tools, Encouraging the Continued Adoption and Practice of More Personalized Medicine Around the World
GE HealthCare has introduced new technologies at the SNMMI 2024 meeting to enhance precision and personalized medicine globally.
The additions include MINItrace Magni, a compact cyclotron for in-house PET tracer production; Omni Legend 21 cm, a versatile PET/CT scanner; and Clarify DL, a deep learning reconstruction tech for clear imaging. These innovations aim to address global healthcare disparities, especially in underserved regions where access to diagnostic imaging is
The company also highlighted its recently acquired MIM Software solutions, which support precise, connected, and efficient care across disease states. A pharmaco-economic study suggests that using a breast oncology PET tracer in diagnostics may save the US healthcare system $142M over five years.
- Introduction of MINItrace Magni for in-house PET tracer production.
- Launch of Omni Legend 21 cm, a versatile and high-performance PET/CT scanner.
- Clarify DL technology for improved imaging accuracy through deep learning.
- TRACERcenter designed to serve as a complete PET radiopharmacy solution.
- Omni Legend mobile for increased access in remote or underserved areas.
- Acquisition of MIM Software to enhance precision care with digital solutions.
- Pharmaco-economic study shows potential $142M savings over five years using PET/CT with a breast oncology PET tracer.
- Operational challenges due to healthcare resource and staff shortages.
- Global healthcare disparities with two-thirds of the population lacking access to diagnostic imaging.
- Limitations of traditional radioisotope generators posing challenges in precision care adoption.
GE HealthCare's recent announcements encompass multiple advancements in medical technology aimed at enhancing the accessibility and efficacy of personalized medicine. The introduction of the MINItrace Magni, a compact cyclotron for in-house production of PET tracers, addresses a critical bottleneck in the supply of radiopharmaceuticals. This innovation is likely to mitigate the logistical challenges involved in sourcing tracers, thus potentially increasing the reliability and timeliness of diagnostic imaging services, especially for oncology, cardiology and neurology.
The development of the Omni Legend 21 cm further augments GE’s capabilities in precision care. This PET/CT system is designed to evolve with healthcare demands, featuring deep learning reconstruction and enhanced workflow efficiencies. Its ability to reduce radiation dose while maintaining image quality is a significant enhancement, particularly in Theranostics where precise imaging is important for effective treatment planning. The system’s scalability ensures that it can adapt to future technological advancements, which is a key consideration for long-term investment in medical equipment.
In addition, the introduction of Clarify DL, a deep learning reconstruction technology, marks a noteworthy advancement in image processing by reducing noise without compromising contrast. This capability is vital for accurate diagnostics and monitoring in personalized medicine, enhancing confidence in treatment decisions. The acquisition of MIM Software further strengthens GE’s portfolio, providing advanced digital solutions that streamline workflows and improve diagnostic accuracy and efficiency.
From a medical research perspective, these developments collectively signify a substantial stride towards more effective and accessible precision care, potentially improving patient outcomes and operational efficiencies globally.
GE HealthCare’s suite of new products and technologies represents not just advancements in medical imaging but also strategic moves that could have positive financial implications. The focus on in-house production of PET tracers addresses a significant pain point in the diagnostic imaging supply chain. This could translate into cost savings for healthcare providers and increase the adoption rates of GE’s solutions, thereby driving revenue growth.
The Omni Legend 21 cm PET/CT system, with its scalable design and AI-enhanced features, is poised to meet the growing demand for precise and efficient diagnostic tools. Its capabilities align with current trends towards low-dose imaging and theranostics, both of which are gaining traction within the medical community. This product could capture significant market share in an expanding segment, especially given its adaptability to future advancements.
The acquisition of MIM Software enhances GE’s digital health portfolio, providing advanced imaging solutions that complement their hardware offerings. These software solutions are essential for optimizing imaging workflows and improving diagnostic accuracy, making them attractive to healthcare providers looking for comprehensive, integrated solutions. The potential for cost savings highlighted in the breast cancer diagnostic study further underscores the economic value these technologies bring to the healthcare ecosystem.
From a financial perspective, these innovations and acquisitions likely strengthen GE HealthCare’s market position, potentially leading to increased market penetration, higher revenue streams and enhanced shareholder value.
- At #SNMMI24, GE HealthCare expands its technology with the addition of a MINItrace Magni,i designed to be a small footprint cyclotron for reliable, in-house production of commercial PET tracers and radiometals; Omni Legend 21 cm, ii a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands across care areas; and Clarify DL,iii a new deep learning reconstruction technology designed to deliver clear, accurate, and effortless imaging
- Combined with GE HealthCare’s well-established portfolio – including portable systems to reach remote populations and refurbished medical equipment to help improve access to affordable, quality healthcare – these technologies and the Company’s recently acquired MIM Software solutions aim to expand global access to precision care
More than half of the world’s population is underserved and lacks access to essential health services,iv and two-thirds have no access to diagnostic imaging.v Yet even those who have these services and systems within reach may struggle to receive necessary scans due to the challenges healthcare providers often face in reliably sourcing commercial PET tracers – leaving many patients and medical centers around the world without recourse. These shortfalls, in addition to ongoing healthcare resource and staff shortages,vi challenge the adoption of precision care globally.
“It’s not enough to develop cutting-edge solutions if they aren’t also made more accessible to clinicians and patients around the world,” shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. “While there is still much work to be done, we are proud to offer a variety of technologies that can evolve with healthcare system needs and help support a patient’s entire care journey – from the systems required to create the radiotracers used to diagnose and monitor disease, to the imaging equipment used for a noninvasive look at a patient’s anatomy and treatment monitoring, to the software optimized to measure lesion size and dose. In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”
As clinicians seek to practice more personalized medicine – including Theranostics, a type of precision care that combines diagnostics and therapy – they increasingly look to leverage imaging techniques that more accurately inform diagnoses and measure functional and molecular responses to therapy.
Increasing access to better support patient care
GE HealthCare aims to design and develop a range of products that support these efforts, empowering global healthcare providers to address the needs of all patient populations.
For the practice of precision care in molecular imaging and nuclear medicine, this begins with the production of radioisotopes for use in diagnostic tracers, which are administered to patients, attach to specific biomarkers, and release radioactive emissions to provide clinicians detailed molecular information unique to each patient.
However, as the positive and exponential rise of Theranostics drives greater demand for these radioisotopes (or tracers), the limitations of traditionally used generators have created serious challenges for clinicians and limited patient access.
In response, GE HealthCare is proud to announce the development of its new MINItrace Magni,i designed to be a small footprint, cost effective cyclotron for reliable, in-house production of commercial PET tracers and radiometals – like Gallium-68 – through solid target technology. When produced in combination with the company’s TRACERcenter – which is designed to serve as a complete PET radiopharmacy solution – the resulting radiopharmaceuticals can help physicians identify and diagnose clinical signs across care areas – including oncology, cardiology, and neurology.vii
Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system, but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities.
GE HealthCare also designs its systems with accessibility and longevity in mind, recognizing that once a system is acquired for a community, it will be depended on for many years to come.
To this end, GE HealthCare is excited to broaden its Omni platform with Omni Legend 21 cm,ii a performance-focused PET/CT that is designed to evolve and help meet growing healthcare system demands across care areas, including: striking image quality in oncology; an ability to accommodate increasing PET amyloid imaging volume related to Alzheimer's diagnosis in neurology; and impressive imaging of a variety of cardiac tracers, including fast decay tracers and new tracers in cardiology.
These abilities are supported by the system’s innovative 21 cm digital detector designed for augmented NEMA sensitivity,viii in combination with deep learning reconstruction capabilities, advanced digital solutions, and enhanced workflow offerings powered by AI. As a result, Omni Legend is designed to enable clinicians reduce the dose by up to
Additionally, the Omni platform is scalable, allowing radiology departments and healthcare facilities to upgrade the hardware and add service lines to help meet growing demand as well as optimize clinical capabilities, ensure access to the latest technology, and accommodate evolving community needs for many years to come.
GE HealthCare also offers Omni Legend mobile, an all-in-one portable PET/CT solution that makes the company’s impressive Omni Legend system available to regional or local scan centers and hospitals, helping increase access and reduce the amount of travel required for more vulnerable or remote patient communities.
Software as an enabler of precision care
Ultimately, achieving a more personalized and flexible healthcare experience requires fundamental changes in the way healthcare operates. The system must evolve to be smarter, easier, and more collaborative.
Fortunately, the rise and development of digital and artificial intelligence (AI) solutions makes new tools available to clinicians in the practice of precision medicine.
Revealed for the first time at #SNMMI24, Clarify DLiii represents a new deep-learning reconstruction technology trained on bone SPECT images to establish a network designed to reduce noise while maintaining contrast. The result is an AI-powered solution designed to deliver clear, accurate, and effortless imaging – a stark contrast to today’s noise reduction techniques, which typically lower contrast and resolution and may impact accuracy and diagnostic confidence.
The new AI-based solution is designed for GE HealthCare’s cutting-edge StarGuide digital SPECT/CT. The system’s 12 CZT detector design not only scans patients in 3D to provide more information to clinicians but is also optimized for certain theragnostic procedures, which in turn helps clinicians pinpoint the size, shape, and position of lesions with exceptional accuracy. It also helps clinicians evaluate the success of therapies and need for treatment follow up.
StarGuide also offers several additional innovations, such as flexibility in patient scanning, workflow efficiencies that help reduce complexities and processing time in Theranostics as well as scanning protocols, such as Dynamic SPECT imaging.
“Theranostics is awesome – it’s a life extender,” shares Doug, a Theranostics patient scanned on BAMF Health’s StarGuide system. “This is nothing short of a miracle. I can’t believe we’re seeing this in our lifetime.”
In the spirit of advancing Theranostics and providing clinicians additional digital solutions to help improve patient outcomes, GE HealthCare recently acquired MIM Software with the aim of delivering innovative digital solutions – including MIM Encore and MIM SurePlan MRT– across care pathways for precise, connected, and efficient care across disease states. Collectively, MIM Software’s full portfolio of vendor neutral solutions offers clinicians workflow automation and flexible configuration options for excellent flexibility, automation, and efficiency. This includes streamlined processing, structured reporting, fast and high-quality contouring, advanced image fusion, dosimetry capabilities, easy IT integration, and remote access – helping to boost healthcare productivity and promote personalized patient care.
Product life extension & upgrades
GE HealthCare is also proud to offer global refurbished medical equipment, helping to improve access to affordable, quality healthcare. High-quality refurbished medical equipment is a viable diagnostic imaging option for hospitals seeking to stretch their budgets by purchasing used, but still exceptionally good, systems.
Additionally, with technology advancements and software upgrades, the lifespan of equipment can be extended and enhanced to help improve clinical outcomes.
Today’s healthcare access challenges demand creative solutions to solve complex problems. At GE HealthCare, the answer is new and modular systems, innovative digital and AI solutions, and refurbished equipment – all in the pursuit of increasing access to and the practice of precision care for earlier, more precise, and accessible diagnosis and treatment of patients around the world.
For more information on GE HealthCare’s Molecular Imaging and MIM Software solutions, please visit gehealthcare.com and mimsoftware.com. GE HealthCare will also showcase these technologies and solutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting in
Earlier this week, GE HealthCare also announced that in its sponsored pharmaco-economic study, published in peer-reviewed journal PLOS ONE, the incidence, prevalence, diagnostic pathways, and treatments of different patients with metastatic or recurrent breast cancer were analyzed using a combination of widely accepted statistical modelling methods to estimate the clinical and associated economic impact of adding a PET/CT scan with a breast oncology PET tracer to the current standard diagnostic process. The study shows that adding a PET/CT scan with a breast oncology PET tracer may increase the accuracy of knowing the estrogen receptor (ER) status, and increased accuracy may help clinicians select more effective treatments and decrease the rate of re-biopsies, resulting in the potential cost savings of
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a
Follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
i Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked.
ii Omni Legend 21cm is CE marked. Not approved or cleared by
iii Clarify DL is 510(k)-pending with the
iv World Health Organization, World Bank Group. Tracking universal health coverage: 2023 global monitoring report. Sep 2023. https://www.who.int/publications/i/item/9789240080379
v An audit of licensed Zimbabwean radiology equipment resources as a measure of healthcare access and equity - PMC (nih.gov)
vi World Health Organization Secretariat. Global strategy on human resources for health: Workforce 2030.
vii MINItrace Magni is designed to produce the following radionuclides for use across care areas: F, 11C, 13N, 15O, 68Ga, 89Zr, 61/64Cu and more.
viii Omni Legend 21 cm has up to a 1.6x increase in system sensitivity as compared to Discovery MI Gen1 20 cm. Measurements follow NEMA NU 2-2018.
ix Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240607297244/en/
GE HealthCare media contact
Margaret Steinhafel
Global Communications Director
Molecular Imaging & Computed Tomography
M +1 608 381 8829
margaret.steinhafel@gehealthcare.com
Source: GE HealthCare
FAQ
What is GE HealthCare's MINItrace Magni?
What are the features of GE HealthCare's Omni Legend 21 cm PET/CT?
How does Clarify DL improve imaging?
What did GE HealthCare's pharmaco-economic study reveal?
How does GE HealthCare address global healthcare disparities?
What technologies did GE HealthCare unveil at SNMMI 2024?
